Medicus Pharma Ltd.
Medicus Pharma Ltd. is a clinical-stage biotech company focused on developing and advancing novel therapeutic assets, with a current emphasis on skin cancer programs delivered through dissolvable microneedle arrays. It also pursues opportunistic acquisitions and partnerships to broaden its pipeline, including the acquisition of Antev Limited and its Teverelix program.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenueInvestigational non-invasive treatments for basal cell carcinoma and squamous cell carcinoma using D-MNA technology.
Patent-protected dissolvable microneedle array technology used to deliver doxorubicin locally.
Acquired and partnered clinical assets such as Teverelix that expand the oncology/urology pipeline.
Development of D-MNA-based treatment for external squamous cell carcinoma in horses.
Customers
Medicus does not yet sell commercial products; its current customers are clinical trial sites, investigators, CROs, and regulators that enable development of its drug candidates. If approved, its end customers would be physicians, hospitals, and specialty clinics treating skin cancer, prostate cancer, and potentially veterinary oncology cases.
Hospitals and investigators run the BCC studies and generate the clinical data needed for approval.
FDA and UAE DOH review study plans, safety data, and development pathways that determine whether programs can advance.
Contract research organizations coordinate trial operations, site management, and data collection.
Dermatologists, oncologists, and specialty clinics would buy approved skin cancer therapies if commercialization occurs.
Veterinarians treating equine SCC would be the end users for the horse indication if approved.
Strategy
Medicus is building a clinical-stage pipeline around its D-MNA platform while expanding the number of indications and geographies under study. Near term, the company is focused on advancing SKNJCT-003 and SKNJCT-004, while medium term it is trying to add value through acquisitions such as Antev and through regulatory milestones like MUMS and FDA development plans.
Clinical proof-of-concept is the main value driver for the D-MNA platform and future approvals.
Additional assets reduce dependence on a single program and create more shots on goal.
The company has no product revenue and must fund trials through equity or non-dilutive sources.
Geography
The company is headquartered in the United States and its current development activity is centered there, with SKNJCT-003 running across nine U.S. clinical sites. It is also expanding into Europe and the UAE for clinical development, while Antev adds a UK-based operating footprint and future development exposure.
Risks
The company is exposed to classic clinical-stage biotech risks: trial failure, regulatory setbacks, and the need for continuous external funding. Its recent acquisition strategy adds integration risk, while geographic expansion into the UAE and Europe increases operational complexity and dependence on third-party sites and CROs.
- Financing riskImpact: Critical
The company currently has no operating revenue and must fund R&D through equity or other sources.
Exposure: Ongoing trial and corporate spend
- Clinical trial failure for D-MNA programsImpact: High
The company’s value depends on positive efficacy and safety results from SKNJCT studies.
Exposure: SKNJCT-003 and SKNJCT-004
- Regulatory delay or non-approvalImpact: High
Advancement to later-stage development and commercialization requires FDA and local approvals.
Exposure - Acquisition integration riskImpact: MediumLikelihood: Medium
Antev may be difficult to integrate and Teverelix may not develop as expected.
Exposure: Antev Limited acquisition
- Operational complexity across geographiesImpact: MediumLikelihood: Low
Multi-country trials require coordination across hospitals, CROs, and regulators.
Exposure
Accounting
Judgemental itemsClinical and preclinical costs are recognized immediately, making earnings highly sensitive to trial timing.
Impact: Reported losses rise as SKNJCT and acquisition-related development spend increases
The company states it must continue financing operations through equity or non-dilutive sources.
Impact: Material for liquidity and solvency analysis
Fair value assumptions affect non-cash compensation expense.
Impact: Can materially affect operating loss in a small-cap biotech
Common shares, warrants, convertible notes, and debentures require careful classification and measurement.
Impact: Affects dilution, interest/other finance income or expense, and equity balances
Similar listed companies
Publicly listed companies with a comparable business focus.
Kairos Pharma, LTD.
KAPA · Pharmaceutical Preparations
Teva Pharmaceutical Industries Limited
TEVA · Pharmaceutical Preparations
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
PMV Pharmaceuticals, Inc.
PMVP · Pharmaceutical Preparations
PMV Pharmaceuticals is a U.S.-based clinical-stage biotechnology company focused on developing small-molecule cancer therapies, with an emphasis on genomically defined tumors.
MediciNova, Inc
MNOV · Pharmaceutical Preparations
MedicNova Inc.
Medivir
MVIR · Health Care
Medivir AB is a Swedish pharmaceutical company focused on the development of innovative treatments for serious diseases.
Last updated: 24/09/2026